Synlogic to Study SYNB1891 With Roche's Tecentriq in Advanced Solid Tumors

Date : 05/22/2019 @ 12:19PM
Source : Dow Jones News
Stock : Roche Holding (QX) (RHHBY)
Quote : 37.6  0.11 (0.29%) @ 9:14PM

Synlogic to Study SYNB1891 With Roche's Tecentriq in Advanced Solid Tumors

Synlogic (NASDAQ:SYBX)
Historical Stock Chart

6 Months : From May 2019 to Nov 2019

Click Here for more Synlogic Charts.

By Colin Kellaher


Synlogic Inc. (SYBX) on Wednesday said it plans to study its SYNB1891 Synthetic Biotic medicine in combination with Roche Holding AG's (ROG.EB) cancer immunotherapy Tecentriq in patients with advanced solid tumors under a collaboration with the Swiss drugmaker.

Synlogic, a Cambridge, Mass., clinical-stage biopharmaceutical company, said it expects to file an investigational new drug application with the U.S. Federal Drug Administration to begin an open-label Phase 1 clinical trial evaluating SYNB1891 as a monotherapy and a combination treatment with Tecentriq.

Synlogic said it will sponsor the study, while Roche will provide the clinical supply of Tecentriq.


Write to Colin Kellaher at


(END) Dow Jones Newswires

May 22, 2019 08:04 ET (12:04 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest RHHBY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.